Latest news with #RaySearchLaboratories
Yahoo
22-05-2025
- Business
- Yahoo
Bulletin from the Annual General Meeting 2025
The Annual General Meeting 2025 of RaySearch Laboratories AB (publ) was held on May 22, 2025, in Stockholm, Sweden. The following resolutions were adopted. STOCKHOLM, May 22, 2025 /PRNewswire/ -- It was resolved to re-elect Carl Filip Bergendal, Johan Löf, Günther Mårder, Britta Wallgren and Hans Wigzell as Board members of the company and to re-elect Hans Wigzell as Chairman of the Board. The Annual General Meeting adopted the balance sheets and income statements and discharged the members of the Board and the CEO from liability. It was resolved, in accordance with the Board's proposal, on a dividend of SEK 3 per share and that the remaining accumulated profit, amounting to SEK 187,755,281 be brought forward and balanced in the new accounts. The record date for the dividend was determined to be May 26, 2025. It was resolved that remuneration to Board members who do not receive a salary from any Group company, shall amount to SEK 840,000 to the Chairman of the Board and SEK 300,000 to each of the other Board members elected by the general meeting. It was resolved, in accordance with the Board's proposal, to re-elect the auditing firm Deloitte AB as auditor for the period until the next Annual General Meeting. Further, it was resolved that the auditor's fees be paid in accordance with approved invoicing. The Annual General Meeting also resolved to approve the Board's remuneration report for 2024 and to adopt the Board's proposal for guidelines on executive remuneration. More information and complete documentation relating to the Annual General Meeting is available at About RaySearch RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation®* treatment planning system (TPS) and the oncology information system (OIS) RayCare®*. The most recent additions to the RaySearch product line are RayIntelligence® and RayCommand®*. RayIntelligence is an oncology analytics system (OAS) which enables cancer clinics to collect, structure and analyze data. RayCommand, a treatment control system (TCS), is designed to link the treatment machine and the treatment planning and oncology information systems. RaySearch's software has been sold to over 1,100 clinics in 47 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003. More information is available at * Subject to regulatory clearance in some markets. For more information, please contact:Johan Löf, founder and CEO, RaySearch Laboratories AB (publ)Telephone: + 46 (0) 8 510 530 Nina Grönberg, CFO, RaySearch Laboratories AB (publ)Telephone: + 46 (0) 8 510 530 This information was brought to you by Cision The following files are available for download: RaySearch Press Release May 22, 2025 View original content: SOURCE RaySearch Laboratories
Yahoo
14-05-2025
- Business
- Yahoo
High Growth Tech Stocks in Europe for May 2025
As the pan-European STOXX Europe 600 Index continues its upward trajectory, marking a fourth consecutive week of gains amid easing trade tensions between China and the U.S., investors are closely watching how these developments influence high-growth tech stocks in Europe. In this dynamic environment, identifying promising tech stocks involves assessing their ability to innovate and adapt to shifting market conditions while leveraging opportunities presented by evolving trade relationships. Name Revenue Growth Earnings Growth Growth Rating Archos 21.07% 36.58% ★★★★★★ Yubico 22.16% 27.03% ★★★★★★ KebNi 21.29% 66.10% ★★★★★★ Pharma Mar 25.21% 43.09% ★★★★★★ Skolon 31.51% 99.52% ★★★★★★ Elicera Therapeutics 63.53% 97.24% ★★★★★★ Ascelia Pharma 43.57% 77.62% ★★★★★★ Elliptic Laboratories 23.60% 51.89% ★★★★★★ CD Projekt 33.48% 37.39% ★★★★★★ Xbrane Biopharma 24.95% 56.77% ★★★★★★ Click here to see the full list of 223 stocks from our European High Growth Tech and AI Stocks screener. We'll examine a selection from our screener results. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Grifols, S.A. is a plasma therapeutic company with operations in Spain, the United States, Canada, and other international markets, and it has a market capitalization of approximately €5.55 billion. Operations: Grifols generates revenue primarily from its Biopharma segment, which accounts for €6.14 billion, followed by the Diagnostic and Bio Supplies segments with €644.90 million and €215.66 million respectively. Grifols has demonstrated robust financial performance with a 270.8% surge in earnings over the past year, significantly outpacing the biotech industry's average of 31.3%. This growth is underpinned by a strategic focus on specialty diagnostics, highlighted by their recent partnership with IBL International to develop biomarker panels, enhancing Grifols' offerings in high-value diagnostic solutions. Additionally, Grifols' commitment to R&D is evident from its substantial investment in innovation, which positions the company well for sustained growth amid dynamic market demands. The firm's proactive approach in forming strategic alliances and expanding its technological base underscores its potential to maintain momentum and adapt to evolving industry landscapes. Delve into the full analysis health report here for a deeper understanding of Grifols. Review our historical performance report to gain insights into Grifols''s past performance. Simply Wall St Growth Rating: ★★★★☆☆ Overview: RaySearch Laboratories AB (publ) is a medical technology company that develops software solutions for cancer treatment globally, with a market capitalization of SEK11.18 billion. Operations: RaySearch Laboratories generates revenue by providing advanced software solutions for cancer treatment across the globe. The company's financial performance is reflected in its market capitalization of SEK11.18 billion, with notable trends in its net profit margin percentage. RaySearch Laboratories, a beacon in the European tech landscape, has recently showcased significant financial and strategic growth. In the first quarter of 2025, the firm saw its sales climb to SEK 331.7 million from SEK 257.2 million year-over-year, coupled with a net income increase to SEK 56.81 million from SEK 36.7 million, reflecting an earnings surge of over 122% compared to the previous year. These robust figures are underpinned by RaySearch's aggressive investment in R&D and strategic alliances such as their integration with Vision RT's MapRT in their RayStation system, enhancing radiation therapy planning precision and efficiency. This focus not only drives revenue growth at an impressive annual rate of 12.7% but also solidifies its market position by adapting swiftly to evolving oncological needs through technological innovation. Navigate through the intricacies of RaySearch Laboratories with our comprehensive health report here. Gain insights into RaySearch Laboratories' historical performance by reviewing our past performance report. Simply Wall St Growth Rating: ★★★★☆☆ Overview: ALSO Holding AG, with a market cap of CHF3.32 billion, operates as a technology services provider for the ICT industry across Switzerland, Germany, the Netherlands, Poland, and other international markets. Operations: With a focus on technology services, the company generates revenue primarily from Central Europe (€4.72 billion) and Northern/Eastern Europe (€5.24 billion). ALSO Holding AG is strategically expanding its footprint in the high-growth cybersecurity sector, recently launching new products tailored for SMBs through its partnership with CYE. This initiative taps into a burgeoning European cybersecurity market projected to hit EUR 70 billion by 2030, addressing the acute need for manageable security solutions amidst a complex landscape with over 3,000 vendors. Financially, ALSO reported a slight dip in annual sales to EUR 9.51 billion from EUR 9.96 billion and net income decreased to EUR 115.05 million from EUR 123.66 million year-over-year. Despite these challenges, the company's forward-looking revenue growth at an annual rate of 8.9% and earnings growth forecast at an impressive 21.1% per year underscore its potential resilience and adaptability in navigating market shifts and capitalizing on strategic innovations within tech-driven sectors. Dive into the specifics of ALSO Holding here with our thorough health report. Explore historical data to track ALSO Holding's performance over time in our Past section. Explore the 223 names from our European High Growth Tech and AI Stocks screener here. Are any of these part of your asset mix? Tap into the analytical power of Simply Wall St's portfolio to get a 360-degree view on how they're shaping up. Simply Wall St is your key to unlocking global market trends, a free user-friendly app for forward-thinking investors. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include BME:GRF OM:RAY B and SWX:ALSN. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
Yahoo
15-04-2025
- Business
- Yahoo
High Growth Tech Stocks in Europe for April 2025
In the midst of escalating trade tensions and fluctuating consumer sentiment, European markets have experienced a turbulent period, with the pan-European STOXX Europe 600 Index ending 1.92% lower amid heightened vigilance from central banks. As investors navigate this complex landscape, identifying high growth tech stocks that can withstand market volatility becomes crucial; these companies often demonstrate resilience through innovation and adaptability in challenging economic climates. Name Revenue Growth Earnings Growth Growth Rating Pharma Mar 24.24% 40.82% ★★★★★★ Yubico 20.08% 25.52% ★★★★★★ Elicera Therapeutics 63.53% 97.24% ★★★★★★ Devyser Diagnostics 26.28% 96.54% ★★★★★★ Xbrane Biopharma 33.71% 82.67% ★★★★★★ CD Projekt 33.78% 37.39% ★★★★★★ XTPL 97.45% 117.95% ★★★★★★ Skolon 29.76% 91.18% ★★★★★★ Elliptic Laboratories 49.76% 88.21% ★★★★★★ Ascelia Pharma 46.09% 66.93% ★★★★★★ Click here to see the full list of 230 stocks from our European High Growth Tech and AI Stocks screener. We'll examine a selection from our screener results. Simply Wall St Growth Rating: ★★★★★☆ Overview: RaySearch Laboratories AB (publ) is a medical technology company that offers software solutions for cancer care across various regions including the Americas, Europe, Africa, the Asia-Pacific, and the Middle East, with a market cap of SEK7.71 billion. Operations: The company generates revenue primarily from its healthcare software segment, amounting to SEK1.19 billion. RaySearch Laboratories, a leader in advanced radiation therapy technology, has demonstrated robust financial and operational growth. In the past year, its earnings surged by 149.5%, significantly outpacing the Healthcare Services industry's growth of 28.2%. This performance is underpinned by strategic expansions such as the recent SEK 500 million equity offering and a significant new order from Heyou Hospital in China for its cutting-edge RayStation treatment planning system. These developments not only enhance RaySearch's market presence but also align with the growing demand for precise particle treatments in oncology—a sector where RaySearch is setting global standards. With an expected annual earnings growth of 23.7% over the next three years, RaySearch is well-positioned to maintain its trajectory amidst evolving healthcare technologies. Navigate through the intricacies of RaySearch Laboratories with our comprehensive health report here. Assess RaySearch Laboratories' past performance with our detailed historical performance reports. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Sinch AB (publ) is a global provider of cloud communications services and solutions for enterprises and mobile operators, with a market capitalization of SEK17.04 billion. Operations: Sinch AB (publ) generates revenue through its cloud communications services across key regions, with the Americas contributing SEK18.11 billion, EMEA SEK6.64 billion, and APAC SEK3.96 billion. Sinch, navigating through a challenging fiscal period marked by a net loss of SEK 324 million in Q4 2024, contrasts sharply with the previous year's profit. Despite this setback, the company is poised for recovery with strategic alliances such as its recent partnership with Aduna to enhance global digital service innovations via network APIs. This collaboration underscores Sinch's commitment to integrating cutting-edge communication capabilities into diverse platforms, bolstering its role in advancing tech infrastructure. With an anticipated shift towards profitability and a revenue growth forecast at 3.4% annually—above Sweden's average—Sinch is strategically positioning itself for sustainable growth in the evolving tech landscape. Delve into the full analysis health report here for a deeper understanding of Sinch. Learn about Sinch's historical performance. Simply Wall St Growth Rating: ★★★★☆☆ Overview: ALSO Holding AG, along with its subsidiaries, serves as a technology services provider for the ICT industry across Switzerland, Germany, the Netherlands, Poland, and other international markets with a market cap of CHF2.82 billion. Operations: The company generates revenue primarily from its operations in Central Europe (€4.72 billion) and Northern/Eastern Europe (€5.24 billion). ALSO Holding, with a robust 8.9% annual revenue growth and an impressive 21.1% expected earnings growth per year, is outpacing the Swiss market average significantly. The company's commitment to innovation is evident from its R&D investments, which have been pivotal in maintaining competitive advantage and driving future growth prospects. Recent strategic initiatives include a dividend increase to CHF 5.10 and significant IT enhancements aimed at operational excellence, such as the implementation of SAP S/4HANA across its operations by 2029. These efforts not only reflect ALSO's focus on efficiency but also underscore its potential in leveraging technology to sustain its market position and enhance shareholder value in a dynamic industry landscape. Unlock comprehensive insights into our analysis of ALSO Holding stock in this health report. Gain insights into ALSO Holding's past trends and performance with our Past report. Click through to start exploring the rest of the 227 European High Growth Tech and AI Stocks now. Got skin in the game with these stocks? Elevate how you manage them by using Simply Wall St's portfolio, where intuitive tools await to help optimize your investment outcomes. Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include OM:RAY B OM:SINCH and SWX:ALSN. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
